...
首页> 外文期刊>Future Rheumatology >Management of mixed connective tissue disease
【24h】

Management of mixed connective tissue disease

机译:混合性结缔组织病的治疗

获取原文
获取原文并翻译 | 示例

摘要

Mixed connective tissue disease (MCTD) is a systemic autoimmune rheumatic disease manifesting as specific clinical features in the presence of antibodies reactive with the extractable nuclear antigen U1-ribonucleoprotein. It has been described across geographic and ethnic groups. The exact prevalence of MCTD is unknown, but it is usually less common than systemic lupus erythematosus, but more common than systemic sclerosis or dermatomyositis in the populations reported. The clinical features most often present in those with MCTD include: arthralgias/arthritis, Raynaud’s phenomenon, decreased esophageal motility, decreased pulmonary diffusing capacity, swollen hands and myositis. The therapeutic plan for MCTD needs to be tailored to the specific clinical manifestations present in each patient. Particular attention should be given to early recognition of pulmonary involvement.
机译:混合性结缔组织病(MCTD)是一种全身性自身免疫性风湿性疾病,在与可提取核抗原U1-核糖核蛋白具有反应性的抗体存在下,表现为特定的临床特征。已经在地理和种族群体中进行了描述。目前尚不清楚MCTD的确切患病率,但在报告的人群中,其发病率通常不及系统性红斑狼疮,但较系统性硬化症或皮肌炎更为普遍。 MCTD患者最常出现的临床特征包括:关节痛/关节炎,雷诺现象,食道运动性降低,肺弥散能力降低,手肿和肌炎。 MCTD的治疗计划需要针对每个患者中存在的特定临床表现进行调整。应特别注意早期发现肺部受累。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号